Workflow
BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market

Core Insights - BioCryst Pharmaceuticals has successfully completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million upfront, with potential future milestones of up to $14 million based on sales in Central and Eastern Europe [1][2][3] - The divestiture is expected to improve BioCryst's operating margin as the European business was approximately breakeven on a direct basis [2] - Following the sale, BioCryst will concentrate on increasing ORLADEYO sales in the US market while Neopharmed Gentili will manage commercialization in Europe [2][3] - Despite the loss of European revenue, BioCryst is projected to meet the upper half of its 2025 revenue guidance range of $580 million to $600 million [3] Financial Impact - The transaction is valued at $250 million upfront, which will enhance BioCryst's financial position [1] - Future milestones could add an additional $14 million based on performance in specific European markets [1] Strategic Focus - BioCryst will shift its focus to the US market for ORLADEYO sales, indicating a strategic realignment post-divestiture [2][3] - Neopharmed Gentili will retain the European commercial organization established by BioCryst, ensuring operational continuity in Europe [2]